org-2766 and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic-acid

org-2766 has been researched along with 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic-acid* in 1 studies

Other Studies

1 other study(ies) available for org-2766 and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic-acid

ArticleYear
Org 2766 prevents disruption of vestibular compensation by an NMDA receptor antagonist.
    European journal of pharmacology, 1994, Jan-24, Volume: 252, Issue:1

    The adrenocorticotrophic hormone fragment 4-9 (ACTH-(4-9)) analog, Org 2766 has been shown to accelerate vestibular compensation. However, N-methyl-D-aspartate (NMDA) receptor antagonists disrupt the recovery process. When Org 2766 was administered at a dose of 20 nmol/kg every 4 h for 52 h, it prevented the disruption of compensation usually produced by a single 5 mg/kg i.p. injection of the NMDA receptor antagonist 3-([+]-2-carboxy-piperazin-4yl)-propyl-1-phosphonic acid (CPP). NMDA receptor antagonists and ACTH-like peptides may produce their effects on compensation by acting directly or indirectly at the same receptor complex.

    Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Guinea Pigs; Peptide Fragments; Piperazines; Receptors, N-Methyl-D-Aspartate; Vestibular Function Tests; Vestibule, Labyrinth

1994